ePrints

Prevention of recurrence of atypical hemolytic uremic syndrome post renal transplant with the use of higher-dose eculizumab

Lookup NU author(s): Professor Tim Goodship

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Eculizumab, a terminal complement inhibitor, has recently been used successfully to both prevent and treat the recurrence of atypical hemolytic uremic syndrome (aHUS) post renal transplantation. We describe a case that highlights the need to monitor the effects of eculizumab on the complement system and in this case alter the dosage. Despite taking the standard recommended dose of eculizumab for an adult, this aHUS patient developed a low-grade thrombotic microangiopathy on biopsy within months of renal transplantation. Complement assays (trough CH50) showed small amounts of residual terminal pathway activity suggesting inadequate complement blockade on 1,200 mg eculizumab every 2 weeks. Following an increase in the dose of eculizumab to 1,500 mg every 2 weeks, lactate dehydrogenase (LDH), proteinuria, and creatinine decreased, and CH50 assay showed 0%. This case emphasizes the need to monitor clinical parameters and complement activity to ensure that adequate therapeutic blockade is achieved.

Publication metadata

Author(s): Riddell A, Goodship T, Bingham C

Publication type: Article

Publication status: Published

Journal: Clinical Nephrology

Year: 2016

Volume: 86

Issue: 4

Pages: 200-202

Print publication date: 01/10/2016

Acceptance date: 01/01/1900

ISSN (print): 0301-0430

Publisher: Dustri-Verlag

URL: http://dx.doi.org/10.5414/CN108808

DOI: 10.5414/CN108808

Altmetrics

Share